Investors in Guangzhou Kingmed Diagnostics Group (SHSE:603882) Have Unfortunately Lost 77% Over the Last Three Years
Investors in Guangzhou Kingmed Diagnostics Group (SHSE:603882) Have Unfortunately Lost 77% Over the Last Three Years
As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an overall portfolio. So spare a thought for the long term shareholders of Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882); the share price is down a whopping 78% in the last three years. That'd be enough to cause even the strongest minds some disquiet. The more recent news is of little comfort, with the share price down 54% in a year. Furthermore, it's down 19% in about a quarter. That's not much fun for holders. Of course, this share price action may well have been influenced by the 12% decline in the broader market, throughout the period.
每个投资者都知道,不是每一次动作都能击中甜点。但是巨大的亏损会严重拖累整个投资组合。因此,请为金域医学股份有限公司的长期股东着想(SHSE:603882);股价在过去的三年中惨跌78%。即使是最强大的头脑也会感到不安。最近的消息也没有太多安慰,股价在一年内下跌了54%。此外,大约一个季度下跌了19%。这对持有者来说并不好玩。当然,在这段时间内,股价的走势可能受到了市场整体下跌12%的影响。
Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.
由于股东们长期以来都亏损了,因此让我们回顾过去一段时间的基本面,看看是否一直与收益相一致。
In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
沃伦·巴菲特在他的文章《格雷厄姆与多德维尔的超级投资者》中描述了股票价格并不总是合理地反映了一家企业的价值。考虑市场对一家公司的看法如何转变的一种不完美但简单的方法,是将每股收益(EPS)的变化与股价的动态进行比较。
Guangzhou Kingmed Diagnostics Group saw its EPS decline at a compound rate of 38% per year, over the last three years. The 40% average annual share price decline is remarkably close to the EPS decline. That suggests that the market sentiment around the company hasn't changed much over that time, despite the disappointment. It seems like the share price is reflecting the declining earnings per share.
金域医学的每股收益以复合年均38%的速度下降,在过去的三年中。40%的年均股价下跌与每股收益下降非常接近。这表明市场对公司的情绪在这段时间内并没有多大的变化,尽管令人失望。看起来股价反映了每股收益下降。
The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).
下图显示了EPS随时间的变化情况(如果您单击该图像,则可以查看更多详细信息)。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240812/0-d2d0e6241b6da97fd4d930e8fa01eed3-0-14fe7f8675f18bd7467b47c204b183f7.png/big)
This free interactive report on Guangzhou Kingmed Diagnostics Group's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.
如果您想进一步调查该股票,则广州金域医学集团的免费交互式报告涵盖了其收益、营业收入和现金流等方面,是一个很好的起点。
A Different Perspective
不同的观点
We regret to report that Guangzhou Kingmed Diagnostics Group shareholders are down 53% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 18%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 6% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Guangzhou Kingmed Diagnostics Group , and understanding them should be part of your investment process.
我们很遗憾地报告说,广州金域医学集团的股东在今年下跌了53%(包括分红在内)。不幸的是,这比整个市场下跌18%还要糟糕。然而,它可能仅仅是因为股价受到了整个市场的担忧影响。如果有好的机会的话,认真研究基本面可能是值得的。遗憾的是,去年的表现结束了一段糟糕的运营,股东面临着每年6%的总亏损。总的来说,长期股价疲软可能是一个不好的迹象,尽管背道而驰的投资者可能希望研究股票,以期翻转局面。虽然考虑市场条件可能对股价产生不同的影响很值得,但其他因素更为重要。例如,始终存在的投资风险。我们已经确定了3个警告信号与金域医学有关,并且了解它们应该成为您的投资过程的一部分。
But note: Guangzhou Kingmed Diagnostics Group may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但请注意:金域医学可能不是最好的股票买入选择。因此,请查看此免费的利润增长过去(以及进一步的增长预测)的有趣公司列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。